Revance Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Revance Therapeutics is Mark Foley, benoemd in Oct2019, heeft een ambtstermijn van 5.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.07M, bestaande uit 7.2% salaris en 92.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.06% van de aandelen van het bedrijf, ter waarde € 3.78M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.3 jaar en 5.4 jaar.

Belangrijke informatie

Mark Foley

Algemeen directeur

US$10.1m

Totale compensatie

Percentage CEO-salaris	7.2%
Dienstverband CEO	5.1yrs
Eigendom CEO	1.1%
Management gemiddelde ambtstermijn	5.3yrs
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Mark Foley's beloning veranderd ten opzichte van Revance Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$303m
Jun 30 2024	n/a	n/a	-US$304m
Mar 31 2024	n/a	n/a	-US$325m
Dec 31 2023	US$10m	US$720k	-US$324m
Sep 30 2023	n/a	n/a	-US$292m
Jun 30 2023	n/a	n/a	-US$337m
Mar 31 2023	n/a	n/a	-US$341m
Dec 31 2022	US$7m	US$673k	-US$356m
Sep 30 2022	n/a	n/a	-US$274m
Jun 30 2022	n/a	n/a	-US$263m
Mar 31 2022	n/a	n/a	-US$274m
Dec 31 2021	US$7m	US$660k	-US$281m
Sep 30 2021	n/a	n/a	-US$297m
Jun 30 2021	n/a	n/a	-US$303m
Mar 31 2021	n/a	n/a	-US$292m
Dec 31 2020	US$9m	US$650k	-US$282m
Sep 30 2020	n/a	n/a	-US$249m
Jun 30 2020	n/a	n/a	-US$209m
Mar 31 2020	n/a	n/a	-US$186m
Dec 31 2019	US$18m	US$190k	-US$159m
Sep 30 2019	n/a	n/a	-US$155m
Jun 30 2019	n/a	n/a	-US$146m
Mar 31 2019	n/a	n/a	-US$143m
Dec 31 2018	US$243k	n/a	-US$143m
Sep 30 2018	n/a	n/a	-US$138m
Jun 30 2018	n/a	n/a	-US$136m
Mar 31 2018	n/a	n/a	-US$128m
Dec 31 2017	US$338k	n/a	-US$121m

Compensatie versus markt: De totale vergoeding ($USD 10.07M ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.03M ).

Compensatie versus inkomsten: De vergoeding van Mark is gestegen terwijl het bedrijf verliesgevend is.

CEO

Mark Foley (59 yo)

5.1yrs

Tenure

US$10,068,915

Compensatie

Mr. Mark J. Foley serves as Chairman of uLab Systems, Inc. He has been Chief Executive Officer at Revance Therapeutics, Inc. since October 13, 2019 and served as its President since October 13, 2019 until...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Foley	CEO & Director	5.1yrs	US$10.07m	1.06% € 3.8m
Tobin Schilke	CFO & Principal Accounting Officer	6yrs	US$3.97m	0.092% € 330.9k
Dwight Moxie	Chief Legal Officer & General Counsel	4.8yrs	US$3.53m	0.046% € 163.1k
Jessica Serra	Head of Investor Relations & ESG	no data	geen gegevens	geen gegevens
Jeanie Herbert	Senior Director of Investor Relations & Corporate Communications	7.9yrs	geen gegevens	geen gegevens
Taryn Conway	Vice President of Marketing	5.6yrs	geen gegevens	geen gegevens
Amie Krause	Chief People Officer	1.7yrs	geen gegevens	geen gegevens
Conor Gallagher	Head of Medical Affairs & Aesthetics	6.5yrs	geen gegevens	geen gegevens
David Hollander	Chief Medical Officer of Global Therapeutics Franchise Lead	1.8yrs	geen gegevens	0.10% € 358.0k
Erica Jordan	Chief Commercial Officer	no data	geen gegevens	0.11% € 391.9k

5.3yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RTI is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Foley	CEO & Director	7.2yrs	US$10.07m	1.06% € 3.8m
Angus Russell	Independent Chairman	10.7yrs	US$346.03k	0.049% € 175.7k
Jill Beraud	Independent Director	5.4yrs	US$317.53k	0.042% € 148.8k
Julian Gangolli	Independent Director	8.3yrs	US$305.03k	0.043% € 153.9k
Vladimir Coric	Independent Director	1.7yrs	US$421.49k	0.020% € 70.9k
Olivia Ware	Independent Director	3.7yrs	US$295.03k	0.030% € 108.0k
Carey Kolaja	Independent Director	3.7yrs	US$304.18k	0.030% € 107.7k
Christian Nolet	Independent Director	5.3yrs	US$315.03k	0.042% € 148.8k

5.4yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RTI wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

Revance Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Revance Therapeutics, Inc. Announces Executive Changes

Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics

CEO & Director recently sold €2.2m worth of stock

CEO & Director recently sold €2.1m worth of stock

Revance Therapeutics, Inc. Appoints David A. Hollander as Chief Medical Officer

Recent updates

Third quarter 2024 earnings released: US$0.37 loss per share (vs US$1.63 loss in 3Q 2023)

Forecast to breakeven in 2026

Crown Laboratories, Inc. entered into a merger agreement to acquire Revance Therapeutics, Inc. (NasdaqGM:RVNC) for approximately $720 million.

Second quarter 2024 earnings released: US$0.36 loss per share (vs US$0.80 loss in 2Q 2023)

Revance Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Insider selling

New minor risk - Profitability

No longer forecast to breakeven

Revance Therapeutics, Inc. Announces the Commercial Launch of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

First quarter 2024 earnings released: US$0.54 loss per share (vs US$0.74 loss in 1Q 2023)

Revance Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Forecast to breakeven in 2026

Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting

Insufficient new directors

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Revance Therapeutics, Inc. Announces Executive Changes

Full year 2023 earnings released: US$3.83 loss per share (vs US$4.90 loss in FY 2022)

Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology

New minor risk - Profitability

Revance Therapeutics, Inc. Reports Consolidated Impairment for the Quarter Ended September 30, 2023

New major risk - Negative shareholders equity

Third quarter 2023 earnings released: US$1.63 loss per share (vs US$1.17 loss in 3Q 2022)

Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics

Revance Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

U.S. FDA Approves First Therapeutic Indication for Revance's Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

Second quarter 2023 earnings released: US$0.80 loss per share (vs US$0.88 loss in 2Q 2022)

Revance Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Share price stability

CEO & Director recently sold €2.2m worth of stock

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.74 loss per share (vs US$0.94 loss in 1Q 2022)

CEO & Director recently sold €2.1m worth of stock

No longer forecast to breakeven

Forecast to breakeven in 2025

Full year 2022 earnings released: US$4.90 loss per share (vs US$4.17 loss in FY 2021)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application for Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

Third quarter 2022 earnings released: US$1.17 loss per share (vs US$1.10 loss in 3Q 2021)

Revance Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Revance Therapeutics, Inc. Submits Supplemental Biologics License Application (sBLA) for DAXXIFY (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Revance Therapeutics, Inc. Appoints David A. Hollander as Chief Medical Officer

Revance Therapeutics, Inc. Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection in the Aesthetic Surgery Journal

Revance to Present Data from Phase 2 Juniper Clinical Trial Evaluating DAXXIFY™ (Daxibotulinumtoxina-Lanm) Injection for the Treatment of Upper Limb Spasticity At the International Congress of Parkinson and Movement Disorder Society (MDS)

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Revance Therapeutics, Inc. Announces FDA Approval of DAXXIFY

Second quarter 2022 earnings released: US$0.88 loss per share (vs US$1.07 loss in 2Q 2021)

Revance Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

First quarter 2022 earnings released: US$0.94 loss per share (vs US$1.08 loss in 1Q 2021)

Revance Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors

Revance Therapeutics, Inc. Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines

Revance Therapeutics, Inc. to Present New Clinical Data on Daxibotulinumtoxin for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting

High number of new directors

Revance Resubmits Biologics License Application for Daxibotulinumtoxin for Injection for Glabellar Lines to the FDA

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Revance Therapeutics, Inc. Announces Executive Changes

Revance Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Claimsfiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc

Revance Therapeutics, Inc. Provides RHA® Collection Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Independent Chairman recently bought €89k worth of stock

Rosen Law Firm Files Class Action Lawsuit Against Revance Therapeutics, Inc

CEO & Director recently bought €458k worth of stock

Third quarter 2021 earnings released: US$1.10 loss per share (vs US$1.34 loss in 3Q 2020)

Second quarter 2021 earnings released: US$1.07 loss per share (vs US$1.12 loss in 2Q 2020)

Board Member recently sold €511k worth of stock

Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from Russell 3000E Value Index